Company intelligence / Profile preview

Spinifex Pharmaceuticals

Stamford, Connecticut, United Statesnovartis.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Spinifex Pharmaceuticals developed EMA401, a first-in-class oral AT2R antagonist for chronic neuropathic pain. Positive Phase II results were published in The Lancet, showing efficacy in post-herpetic neuralgia without central nervous system side effects or serious adverse events. The company was acquired by Novartis for $200 million upfront plus milestones to further develop this approach to peripheral neuropathic pain treatment. Later reports indicate that development of EMA401 was discontinued due to liver toxicity observed during long-term dosing studies in primates.

Therapeutic areas: Neurology
Modalities: Small molecules (specifically angiotensin II type 2 receptor antagonists)
Industry: Biotech

Drug pipeline

1 asset

EMA401

Phase 2

Indications: Neuropathic pain, Post-herpetic neuralgia

Partnerships

No major pharma partnerships prior to acquisition; strong venture capital syndicate including Novo A/S and Canaan Partners.

Beyond the preview

Go deeper on Spinifex Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spinifex Pharmaceuticals.

Explore the full profile